Giordano Caponigro,XIZHONG Huang,Joseph Lehar,Hui-Qin Wang
申请号：
US16526027
公开号：
US20190350935A1
申请日:
2019.07.30
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) at least one c-Met receptor tyrosine kinase inhibitor or pharmaceutically acceptable salt thereof, for simultaneous, separate or sequential administration for the treatment of a proliferative disease, particularly a c-Met dependent proliferative disease； a pharmaceutical composition comprising such combination； a method of treating a subject having a proliferative disease comprising administration of said combination to a subject in need thereof； use of such combination for the treatment of proliferative disease； and a commercial package comprising such combination.
